294 related articles for article (PubMed ID: 14687442)
1. No donepezil discontinuation effect in patients with Alzheimer's disease who were switched to rivastigmine after failing to benefit from donepezil treatment.
Auriacombe S; Pere JJ;
Curr Med Res Opin; 2003; 19(8):715-7. PubMed ID: 14687442
[No Abstract] [Full Text] [Related]
2. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
Bullock R; Bergman H; Touchon J; Gambina G; He Y; Nagel J; Lane R
Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032
[TBL] [Abstract][Full Text] [Related]
3. Comments on Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil.
McRae TD; Schwam EM
Curr Med Res Opin; 2002; 18(6):i-iii; author reply iv-vi. PubMed ID: 12442885
[No Abstract] [Full Text] [Related]
4. [Alzheimer's disease. Foreword].
Derquesné C
Rev Prat; 1998 Nov; 48(17):1871-2. PubMed ID: 9882238
[No Abstract] [Full Text] [Related]
5. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease.
Wilkinson DG; Passmore AP; Bullock R; Hopker SW; Smith R; Potocnik FC; Maud CM; Engelbrecht I; Hock C; Ieni JR; Bahra RS
Int J Clin Pract; 2002; 56(6):441-6. PubMed ID: 12166542
[TBL] [Abstract][Full Text] [Related]
6. Switching cholinesterase inhibitor therapy in Alzheimer's disease--donepezil to rivastigmine, is it worth it?
Bullock R; Connolly C
Int J Geriatr Psychiatry; 2002 Mar; 17(3):288-9. PubMed ID: 11921158
[No Abstract] [Full Text] [Related]
7. Short-term effects of acetylcholinesterase inhibitor treatment on EEG and memory performance in Alzheimer patients: an open, controlled trial.
Brassen S; Adler G
Pharmacopsychiatry; 2003 Nov; 36(6):304-8. PubMed ID: 14663655
[TBL] [Abstract][Full Text] [Related]
8. Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population.
Prasher VP
Int J Geriatr Psychiatry; 2004 Jun; 19(6):509-15. PubMed ID: 15211527
[TBL] [Abstract][Full Text] [Related]
9. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.
Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
Health Technol Assess; 2001; 5(1):1-137. PubMed ID: 11262420
[TBL] [Abstract][Full Text] [Related]
10. Effects of acetyl-L-carnitine in Alzheimer's disease patients unresponsive to acetylcholinesterase inhibitors.
Bianchetti A; Rozzini R; Trabucchi M
Curr Med Res Opin; 2003; 19(4):350-3. PubMed ID: 12841930
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil.
Auriacombe S; Pere JJ; Loria-Kanza Y; Vellas B
Curr Med Res Opin; 2002; 18(3):129-38. PubMed ID: 12094822
[TBL] [Abstract][Full Text] [Related]
12. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.
Bullock R; Touchon J; Bergman H; Gambina G; He Y; Rapatz G; Nagel J; Lane R
Curr Med Res Opin; 2005 Aug; 21(8):1317-27. PubMed ID: 16083542
[TBL] [Abstract][Full Text] [Related]
13. [Alzheimer dementia. Comparison of the effectiveness of cholinesterase inhibitors and gingko].
Gasser US; Gasser T
MMW Fortschr Med; 2001 Dec; 143(51-52):40-1. PubMed ID: 11824165
[No Abstract] [Full Text] [Related]
14. New drugs for Alzheimer's disease.
Burns A; Russell E; Page S
Br J Psychiatry; 1999 Jun; 174():476-9. PubMed ID: 10616624
[No Abstract] [Full Text] [Related]
15. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
Blesa R; Bullock R; He Y; Bergman H; Gambina G; Meyer J; Rapatz G; Nagel J; Lane R
Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484
[TBL] [Abstract][Full Text] [Related]
16. Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors.
Gauthier S; Emre M; Farlow MR; Bullock R; Grossberg GT; Potkin SG
Curr Med Res Opin; 2003; 19(8):707-14. PubMed ID: 14687441
[TBL] [Abstract][Full Text] [Related]
17. Rivastigmine for Alzheimer's disease.
Drug Ther Bull; 2000 Feb; 38(2):15-6. PubMed ID: 10829350
[TBL] [Abstract][Full Text] [Related]
18. New drug treatment for Alzheimer's disease. SMAC's advice on use of donepezil is contradictory.
Baxter T; Black D; Prempeh H
BMJ; 1998 Oct; 317(7163):946. PubMed ID: 9841011
[No Abstract] [Full Text] [Related]
19. Investigation of responders and non-responders to long-term donepezil treatment.
Inoue J; Hoshino R; Nojima H; Ishida W; Okamoto N
Psychogeriatrics; 2010 Jun; 10(2):53-61. PubMed ID: 20738808
[TBL] [Abstract][Full Text] [Related]
20. Cholinesterase inhibitors in Alzheimer's disease: donepezil or rivastigmine?
Sharma JC
Int J Clin Pract; 2002; 56(6):414-5. PubMed ID: 12166537
[No Abstract] [Full Text] [Related]
[Next] [New Search]
